Biotech vs AI vs Climate Tech: How Research Momentum Differs Across the Three Largest Innovation Verticals

Not all research momentum looks the same. AI, biotech, and climate tech collectively account for the majority of investable preprint activity tracked by the Finch Innovation Index, but the shape, speed, and geographic distribution of that activity differ in ways that matter for capital allocation. Treating these three verticals as interchangeable "hot sectors" is a common mistake. Their research dynamics are structurally distinct, and those structural differences predict very different commercialization timelines.

Volume vs Velocity: Why Raw Preprint Counts Mislead

AI-related themes generate the highest absolute preprint volume of any vertical in the Finch Innovation Index dataset. AI preprint output has grown at roughly 3x the rate of biotech preprints over the past five years. But volume alone is a poor proxy for momentum. What matters is acceleration: the rate at which new subthemes emerge, citation networks densify, and keyword clusters shift.

Biotech preprint volume grows more slowly than AI, but biotech subthemes show higher citation velocity per paper on average. This reflects a research ecosystem where individual papers carry more experimental weight; a single preprint describing a novel CRISPR delivery mechanism or protein structure prediction can redirect an entire subfield. In AI, by contrast, incremental architecture improvements generate high volume but often modest per-paper impact outside a narrow community.

Climate tech sits between these two poles. Climate tech preprint volume has accelerated sharply since 2020, driven by themes like solid-state batteries, green hydrogen catalysis, and carbon capture materials. The acceleration is real, but climate tech subthemes are more fragmented than AI or biotech, spanning chemistry, materials science, atmospheric modeling, and energy systems engineering. This fragmentation means that momentum scoring must account for cross-disciplinary convergence, not just within-field acceleration.

Geographic Signatures Reveal Different Innovation Structures

Each vertical concentrates differently across geographies, and these patterns carry investment implications.

AI research is heavily concentrated in the US and China, with those two countries producing the majority of high-citation AI preprints. The US and China together account for an estimated 60 to 70 percent of top-cited AI preprints globally. This bipolar structure means that AI momentum shifts are largely driven by policy, funding, and talent dynamics in two countries.

Biotech research is more geographically distributed than AI. European institutions, particularly in the UK, Germany, and Switzerland, contribute a larger share of high-impact biotech preprints relative to their AI output. Biotech research momentum is more geographically distributed than AI, with Europe contributing a disproportionately large share of high-citation work. This distribution matters for investors evaluating where translational infrastructure, such as regulatory pathways, clinical trial networks, and manufacturing capacity, will most efficiently convert research signals into commercial outcomes.

Climate tech research shows the broadest geographic distribution of the three verticals. Climate tech preprint activity is the most geographically dispersed of the three verticals, with significant contributions from East Asia, Europe, and emerging research economies. Nations with strong materials science traditions, including South Korea, Japan, and several EU member states, contribute outsized preprint activity in battery chemistry and catalysis. The Finch Innovation Index captures these patterns through country-level publication analysis, revealing where research density is building before commercial ecosystems follow.

Momentum Timing and the Commercialization Gap

The gap between research momentum and commercial deployment varies dramatically across verticals. AI has the shortest research-to-deployment cycle of the three major verticals. A transformer architecture improvement published as a preprint can appear in production software within months. This compressed cycle means that preprint signals in AI offer a shorter but still meaningful lead time over market indicators, typically 6 to 18 months.

Biotech operates on fundamentally longer timelines. Biotech research-to-deployment timelines are fundamentally longer than AI, often spanning 5 to 15 years from preprint to approved therapeutic. Preprint momentum in biotech is best read as a signal of where clinical and commercial activity will concentrate half a decade later.

Climate tech timelines fall between AI and biotech but vary enormously by subtheme. Software-heavy climate applications, such as grid optimization and emissions monitoring, can move quickly. Hardware-intensive themes like next-generation photovoltaics or direct air capture require years of pilot-scale validation. Climate tech commercialization timelines vary widely by subtheme, from under two years for software-driven applications to over a decade for hardware-intensive processes.

What This Means for Research-Informed Capital Allocation

Investors using the Finch Innovation Index across these three verticals should calibrate their interpretation of momentum scores to the structural characteristics of each domain. A rising momentum score in AI may signal near-term deployment opportunity. The same score in biotech signals early-stage pipeline formation. In climate tech, the interpretation depends heavily on which subtheme is accelerating.

The Finch Innovation Index tracks 73 investable themes across these and other verticals, applying consistent methodology while surfacing the vertical-specific dynamics that raw data obscures. For analysts building cross-sector views of innovation, understanding these structural differences is not optional. It is the difference between reading the data and reading it correctly.